SCHEMBL626457

SCHEMBL626457

OC(c1ncccn1)C1(c2ccccc2OC(F)(F)F)CCC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.40
HDAC6 Q9UBN7 1/20 0.36
TRPV3 Q8NET8 2/20 0.35
SLC6A9 P48067 3/20 0.34
PKLR P30613 1/20 0.34
BDKRB1 P46663 1/20 0.34
PDK2 Q15119 1/20 0.33
HCRTR1 O43613 2/20 0.32
BACE1 P56817 1/20 0.32
HSD11B1 P28845 1/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
PDE2A O00408 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CYP2C9 P11712 1/20 0.31
EPHX2 P34913 1/20 0.31
CYP2J2 P51589 1/20 0.31
HRH1 P35367 1/20 0.31
SLC40A1 Q9NP59 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL625805 0.88 NR1I2 (0.54) NR1I2HDAC6TRPV3SLC6A9PKLR
SCHEMBL625816 0.78 TRPV3 (0.39) HDAC6TRPV3PDK2HSD11B1
SCHEMBL624825 0.78 NR1I2 (0.57) NR1I2TRPV3SLC6A2SLC6A4PDE2A
SCHEMBL14893962 0.77 NR1I2 (0.51) NR1I2HDAC6TRPV3SLC6A9PKLR
SCHEMBL14894480 0.76 NR1I2 (0.49) NR1I2HDAC6TRPV3SLC6A9PKLR
SCHEMBL624777 0.75 NR1I2 (0.43) NR1I2HDAC6TRPV3SLC6A9PKLR
SCHEMBL14893425 0.75 SLC6A9 (0.36) NR1I2HDAC6SLC6A9PKLRBDKRB1
SCHEMBL12473778 0.74 HSD11B1 (0.39) NR1I2HDAC6SLC6A9PKLRBDKRB1
SCHEMBL14893688 0.74 P2RX7 (0.36) NR1I2HDAC6SLC6A9PKLRBDKRB1
SCHEMBL12473827 0.72 HSD11B1 (0.38) NR1I2HDAC6SLC6A9PKLRBDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2603490-A1 NOVEL TRPV3 MODULATORS AbbVie Inc. (US) 2013-06-19 EP claimed
US-20130150409-A1 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2013-06-13 US claimed
WO-2012019315-A1 NOVEL TRPV3 MODULATORS ABBOTT LABORATORIES (US) 2012-02-16 WO claimed
US-9156788-B2 TRPV3 modulators ABBVIE INC. (US) 2015-10-13 US disclosed
EP-2771322-A2 NOVEL TRPV3 MODULATORS AbbVie Inc. (US) 2014-09-03 EP disclosed
US-8772500-B2 TRPV3 modulators ABBVIE INC. (US) 2014-07-08 US disclosed
US-8772499-B2 TRPV3 modulators ABBVIE INC. (US) 2014-07-08 US disclosed
US-20140080803-A1 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2014-03-20 US disclosed
EP-2603490-A1 NOVEL TRPV3 MODULATORS AbbVie Inc. (US) 2013-06-19 EP disclosed
US-20130150409-A1 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2013-06-13 US disclosed
US-20130131036-A1 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2013-05-23 US disclosed
WO-2013062964-A2 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2013-05-02 WO disclosed
WO-2012019315-A1 NOVEL TRPV3 MODULATORS ABBOTT LABORATORIES (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131036-A1 NOVEL TRPV3 MODULATORS TRPV3, TRPV4, TRPV5 NR1I2 210/4885HDAC6 1363/4885TRPV3 1/4885
US-20130150409-A1 NOVEL TRPV3 MODULATORS TRPV3, TRPV4, TRPV5 NR1I2 219/4885HDAC6 1203/4885TRPV3 1/4885
US-20140080803-A1 NOVEL TRPV3 MODULATORS TRPV3, TRPV4, TRPV5 NR1I2 221/4885HDAC6 1169/4885TRPV3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.